Vertaling van "technological " (Nederlands → Frans) :

(nutrition and public health – University of Ghent) (public health nutrition – University of Ghent) (food chemistry, especially chemical quality and the safety of food – University of Ghent) (industrial microbiology, technology – FUSAGx) (chemistry, additives, contaminants – Free university of Brussels) (chemistry, technology – University of Ghent) (foodstuff analysis – University of Liège) (therapeutic chemistry and nutrition sciences – Free University of Brussels) (toxicology, bromatology – University of Liège) (chemistry, technology – FUSAGx) (paediatric nutrition – University of Liège) (residues and contaminants – University of Liège) (nutritional value of foodstuffs, nutrition and health – University of Ghent)
DE BACKER Guy * (nutrition et santé publique – UGent) DE HENAUW Stefaan * (public health nutrition – UGent) DE MEULENEAR Bruno * (chimie des denrées alimentaires, plus particulièrement la qualité chimique et la sécurité des denrées alimentaires – UGent) DESTAIN Jacqueline * (microbiologie industrielle, technologie – FUSAGx) FONDU Michel * (chimie, additifs, contaminants – ULB) HUYGHEBAERT André* (chimie, technologie – UGent) MAGHUIN-ROGISTER Guy * (analyse des denrées alimentaires – ULg) NEVE Jean * (chimie thérapeutique et sciences nutritionnelles – ULB) NOIRFALIS(S)E Alfred * (toxicologie, bromatologie – ULg) PAQUOT Michel * (chimie, technologie – FUSAGx) RIGO Jacques * (nutrition pédiatrique – ULg) SCIPPO Marie-Louise * (résidus et contaminants – ULg) VAN CAMP John * (valeur nutritionnelle des aliments, alimentation et santé – UGent)

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

- Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies.
- Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, et al. Pathogen inactivation: making decisions about new technologies.

‐ The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
the performance and safety of platelets treated with MIRASOL pathogen reduction technology.

A plan to combat global warming, for instance, steers the whole of society towards a particular technology or approach, in preference to other options.
Un plan de lutte contre le réchauffement climatique, par exemple, guide l'ensemble de la société sur la voie d'une technologie ou d'une approche particulière et en décourage d'autres.

Het is nuttig om er eerst en vooral aan te herinneren dat de term “technologie voor pathogeenreductie” (PRT: pathogen reduction technology) niet noodzakelijk een volledige inactivatie, maar wel een reductie tot gevolg heeft.
Il est nécessaire de rappeler tout d’abord que le terme de technologie de réduction des pathogènes (PRT: pathogen reduction technology) n’a pas nécessairement pour conséquence une inactivation complète mais bien une réduction.

Gebruikte afkortingen: ARDS = acute respiratory distress syndrome; ALI = acute lung injury; CMV = cytomegalovirus; CTCAE = common terminology criteria for adverse events; DNA = desoxyribonucleic acid; CCI = corrected count increment; PRT = pathogen reduction technology; RNA = ribonucleic acid; TRALI = transfusion related acute lung injury; UVA = ultraviolet A light; UVB = ultraviolet B light; UVC = ultraviolet C light.
Abréviations utilisées: ARDS = acute respiratory distress syndrome; ALI = acute lung injury; CMV = cytomégalovirus; CTCAE = common terminology criteria for adverse events; DNA = desoxyribonucleic acid; CCI = corrected count increment; PRT = pathogen reduction technology; RNA = ribonucleic acid; TRALI = transfusion related acute lung injury; UVA = ultraviolet A light; UVB = ultraviolet B light; UVC = ultraviolet C light.

Tweede wedstrijdcyclus voor veelbelovende wetenschappers op het gebied van Health Technology Assessment in België, Duitsland, Nederland en Zwitserland
Un deuxième cycle de concours destiné aux scientifiques prometteurs dans le domaine de l’Évaluation des Technologies de la Santé en Belgique, en Allemagne, aux Pays-Bas et en Suisse

Pfizer start een studiebeurs op in " Health Technology Assessment"
Pfizer lance une bourse d’étude pour la recherche en " Health Technology Assessment"

Het is nuttig om eerst en vooral te verduidelijken dat de term technologie voor pathogeenreductie (PRT: Pathogen Reduction Technology) boven die van virusinactivatie te verkiezen is.
Avant toute chose, il est bon de préciser que le terme de technologie de réduction de pathogènes (PRT: Pathogen Reduction Technology) devrait être préféré à celui de viro-inactivation.